Follow the Actinium Pharmaceuticals, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 4 September 2026 (Attribution). Among the most active insiders: SETH SANDESH. Every trade is openly available.
9
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Actinium Pharmaceuticals, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,576 of 29,063 companies
16.0
score / 100
Value
26
Quality
6
FCF yld-4.0%
Earn yld-1.3%
EV/EBITDA·
ROE-40%
Gross mgn0.0%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Actinium Pharmaceuticals, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias dirigidas para el tratamiento del cáncer. Emplea enfoques innovadores basados en la radioinmunoterapia.